This inventor holds 1 USPTO granted patent. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Ronald Knegiel: Innovator in Protein Kinase Inhibition
Introduction
Ronald Knegiel is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that serve as inhibitors of protein kinases. His work is crucial in the treatment of various diseases, conditions, and disorders.
Latest Patents
Knegiel holds a patent for "Thiophene-carboxamides useful as inhibitors of protein kinases." This invention relates to compounds represented by a specific formula, which are useful in inhibiting protein kinase activity. The patent also includes pharmaceutically acceptable compositions comprising these compounds and outlines methods for their use in treating various health issues. Additionally, it provides processes for preparing the compounds involved in this invention.
Career Highlights
Ronald Knegiel is associated with Vertex Pharmaceuticals, Inc., a leading company in the biotechnology sector. His work at Vertex has allowed him to focus on innovative solutions in drug development, particularly in the area of kinase inhibitors.
Collaborations
Knegiel has collaborated with notable colleagues, including Guy Brenchley and Jean-Damien Charrier. These collaborations have contributed to the advancement of research and development in their field.
Conclusion
Ronald Knegiel's contributions to the field of protein kinase inhibition highlight his innovative spirit and dedication to improving healthcare through scientific advancements. His work continues to impact the pharmaceutical industry positively.